In conclusion, MLH1 V384D polymorphism is associated with primary resistance to EGFR-TKIs in patients with EGFR L858R-positive lung adenocarcinoma and may potentially be a novel biomarker to guide treatment decisions.
This study also suggests that MLH1 -</span>93A>G polymorphisms and ETS exposure have a role in the tumorigenesis o</span>f lung adenocarcinoma among never smokers.